Trials / Completed
CompletedNCT04357860
Clinical Trial of Sarilumab in Adults With COVID-19
Clinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Early administration of sarilumab in hospitalized patients infected with COVID-19 who have pulmonary infiltrates and are at high risk of unfavorable evolution could decrease/prevent progression to acute respiratory distress syndrome (ARDS) requiring high flow nasal oxygenation (HFNO) or either invasive or non-invasive mechanical ventilation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] | Best available treatment up to 14 days plus Sarilumab 200 mg |
| DRUG | Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA] | Best available treatment up to 14 days plus Sarilumab 400 mg |
| DRUG | Best available treatment | Best available treatment up to 14 days |
Timeline
- Start date
- 2020-04-28
- Primary completion
- 2021-03-09
- Completion
- 2021-04-06
- First posted
- 2020-04-22
- Last updated
- 2021-07-07
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT04357860. Inclusion in this directory is not an endorsement.